Navigation Links
Forest Laboratories and Cypress Bioscience to Host Webcast to Discuss Clinical Data Presentations for Milnacipran
Date:11/2/2007

NEW YORK and SAN DIEGO, Nov. 2 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX), and Cypress Bioscience, Inc. (Nasdaq: CYPB) will host a webcast to discuss milnacipran clinical data being presented at the American College of Rheumatology annual conference. The webcast, which will include a slide presentation, will occur on November 8, 2007 at 10:00am EST. Representing Forest Laboratories will be Dr. Lawrence Olanoff, President and Chief Operating Officer of Forest and representing Cypress Bioscience will be Dr. Jay Kranzler, Chairman and Chief Executive Officer of Cypress. Also presenting on the webcast will be Dr. Daniel J. Clauw and Dr. Philip Mease, two milnacipran study investigators that will provide an overview of fibromyalgia syndrome and the current challenges faced by both patients and physicians in managing this complex disease, as well as discuss the milnacipran data findings being presented at ACR.

(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

The webcast can be accessed at the URL: http://phx.corporate- ir.net/phoenix.zhtml?p=irol-eventDetails&c=83198&eventID=1686016 (Due to the length of the link, please copy and paste into you're browser.)

The webcast will also be available on the Forest Laboratories and Cypress Bioscience websites at http://www.frx.com and http://www.cypressbio.com.

A replay of the conference call will be available until December 8, 2007 on both websites.

About Milnacipran:

Milnacipran is a unique dual-reuptake inhibitor, which preferentially blocks the reuptake of norepinephrine with higher potency than serotonin, two neurotransmitters known to play an essential role in regulating pain and mood. It has been approved for the treatment of depression in over 32 countries and has been used by more than 5 million patients during more than 10 years of commercial availability outside the U.S. Milnacipran is being developed for fibromyalgia in the United States market jointly by Forest and its licensor, Cypress Bioscience, Inc.


'/>"/>
SOURCE Forest Laboratories, Inc. and Cypress Bioscience, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Bird flu threat ruled out: Karnataka Forest Department
2. Will The Tropical Forests Survive The Deforestation Scenario?
3. Higher Health Cost Due to Forest Fires
4. Forest Fire Affects Singapores Air Quality
5. India to Protect Its Forests With the Aid of Austrian NGO
6. Human Induced Nitrogen Deposition Increasing Carbon Sequestration in Forests
7. Deforestation Plays a Critical Role in Climate Change: Study
8. China Unveils Green Plan to Revert Farmland to Forest
9. Northern Forests Less Effective Than Tropical Forests in Reducing Global Warming
10. Dr Reddy’s Laboratories to challenge patents on drug
11. Dr Reddy’s Laboratories launches Hyalosy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
Breaking Medicine Technology: